Furthermore, when pargyline was used to treat prostate cancer cells, the expression of pro-apoptotic member NOXA increased significantly, but the expression of anti-apoptotic protein BCL-2 decreased compared with tranylcypromine treatment. This evidence concerns the gene PMAIP1 and prostate carcinoma.